Avadel pharmaceuticals provides corporate update and reports first quarter 2024 financial results

-- generated $27.2 million in net revenue from sales of lumryz™ -- -- through march 31, greater than 2,800 patients enrolled in avadel's ryzup patient support services and more than 1,700 patients initiated therapy --
AVDL Ratings Summary
AVDL Quant Ranking